GLUT2 Cancer Research Results
GLUT2, Glucose Transporter 2: Click to Expand ⟱
| Source: |
| Type: |
GLUT2 is a member of the facilitative glucose transporter family, primarily responsible for the uptake of glucose and other hexoses into cells.
– In cancers like HCC, lower GLUT2 expression sometimes correlates with poorer differentiation and a more aggressive phenotype. As cancer cells shift toward a more glycolytic metabolism, they may rely less on the regulated glucose uptake observed in normal cells, and decreased GLUT2 expression can serve as a marker of this metabolic reprogramming.
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Colon, |
CT26 |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
selectivity↑, Short-term-starvation (STS) was shown to protect normal cells and organs but to sensitize different cancer cell types to chemotherapy
ChemoSen↑, STS potentiated the effects of OXP on the suppression of colon carcinoma growth and glucose uptake in both in vitro and in vivo models.
BG↓, glucose and amino acid deficiency conditions imposed by STS promote an anti-Warburg effect
AminoA↓,
Warburg↓,
OCR↑, characterized by increased oxygen consumption but failure to generate ATP, resulting in oxidative damage and apoptosis.
ATP↓,
ROS↑, a significant increase in O2consumption rate (OCR), indicative of an increased oxidative metabolism, was observed
Apoptosis↑,
GlucoseCon↓, STS was as effective as oxaliplatin (OXP) in reducing the average tumor glucose consumption
PI3K↓, STS and in particular STS+OXP down-regulated the expression of PI3K
PTEN↑, and up-regulated PTEN expression
GLUT1↓, STS induced a profound reduction in GLUT1 , GLUT2 , HKII , PFK1, PK
GLUT2↓,
HK2↓,
PFK1↓,
PKA↓,
ATP:AMP↓, Accordingly, the ATP/AMP ratio, a good indicator of cellular energy charge, was dramatically reduced by the two STS settings
Glycolysis↓, results strongly support the effect of STS on reducing glycolysis and lactate production and increasing respiration at Complexes I-IV resulting in superoxide production/oxidative stress but in reduced ATP generation.
lactateProd↓,
Risk↓, IF has shown potential for reducing cancer risk and enhancing therapeutic efficacy by sensitizing tumor cells to chemotherapy and radiotherapy.
ChemoSen↑, intermittent fasting (IF) may enhance the effectiveness of chemotherapy and targeted therapies by activating autophagy. IF enhances the effectiveness of chemotherapy, including drugs such as cisplatin, cyclophosphamide, and doxorubicin
RadioS↑, disease stabilization, improved response to radiotherapy patients with glioma
*Dose↝, 16:8—16 h of fasting with an 8 h eating window;
*Dose↝, 5:2—consuming a standard number of calories for 5 days and reducing intake to 25% of daily requirements for 2 days;
*Dose↝, Eat–Stop–Eat—complete fasting for 24–48 h.
*LDL↓, IF during Ramadan (approximately 18 h of fasting for 29–30 days) reduces LDL cholesterol levels and increases HDL cholesterol in women, as well as reducing inflammatory markers such as CRP and TNF-α
*CRP↓,
*TNF-α↓,
TumAuto↓, Intermittent fasting activates autophagy as an adaptive mechanism to nutrient deprivation, which may modulate tumor development and treatment
GLUT1↓, fasting reduces the expression of glucose transporters GLUT1/2, which slow down cancer metabolism and increase the susceptibility of cancer cells to oxidative stress
GLUT2↓,
glucose↓, studies on cell and animal models have shown that intermittent fasting reduces glucose and insulin-like growth factor (IGF-1) levels [103], as well as insulin [104,105], resulting in the inhibition of the mTOR kinase pathway (PI3K/Akt/mTOR), suppress
IGF-1↓,
Insulin↓,
mTOR↓,
mTORC1↓, suppression of mTORC1 [22], and activation of AMPK through increased ADP/ATP ratio in cells, which supports autophagy and induces apoptosis
AMPK↑,
Warburg↓, Moreover, IF counteracts the Warburg effect by promoting oxidative phosphorylation, leading to an increase in the production of reactive oxygen species (ROS) and enhanced oxidative stress in cancer cells [106,108], causing DNA damage and the activati
OXPHOS↑,
ROS↑,
DNAdam↑,
JAK1↓, fasting reduces the production of adenosine by cancer cells, inhibiting the activation of the JAK1/STAT pathway, thereby reducing cancer cell proliferation
STAT↓,
TumCP↓,
QoL↑, reduction in IGF-1 levels, improved quality of life patients with multiple cancer types
| - |
in-vitro, |
HCC, |
NA |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
PFK↓,
Glycolysis↓, only inhibited glycolysis in cancer cells with a high rate of aerobic glycolysis (HCC-LM3 and HepG2 cells) but not in low-glycolytic cells (Huh-7 and LO2 cells).
lactateProd↓,
GlucoseCon↓,
TumCP↓,
TumCCA↑, arrests cells in S Phage
Casp3↑, citrate enhanced the EGCG upregulation of active caspase-3 and cleaved-PARP in both HCC-LM3 and HepG2 cells
cl‑PARP↑,
Apoptosis↑,
Casp8↑,
Casp9↑,
Cyt‑c↝, translocation of cytochrome c from the mitochondria into the cytosol
MMP↓,
BAD↑,
GLUT2↓, figure2 c,d
PKM2∅, figure2 c,d
TumCP↓, Our evidence suggested that CP possesses a great potential to inhibit the proliferation of HepG2 cells by targeting the glucose metabolism.
Glycolysis↓,
GlucoseCon↓, CP effectively restrained glucose consumption and lactic acid production.
lactateProd↓,
GLUT1↓, CP treatment led to a substantial decrease in the mRNA expression levels of key glucose transporters (GLUT1 and GLUT3) and glycolytic enzymes (LDHA, HK2, PKM2, and PFK).
GLUT2↓,
LDHA↓,
HK2↓,
PKM2↓,
PFK↓,
Dose↝, key compounds in CP were screened, and apigenin, pinobanksin, pinocembrin, and galangin were identified as potential active agents against glycolysis.
Hif1a↓, Flavonoid components from propolis, as inhibitors of HIF-1, have the ability to regulate critical glycolytic components in cancer cells, including (PKM2), (LDHA), (GLUTs), (HKII), (PFK-1), and (PDK)
Glycolysis↓,
PKM2↓,
LDHA↓,
GLUT2↓,
HK2↓,
PFK1↓,
PDK1↓,
chemoP↓, The positive effects of combining propolis with chemotherapeutics include reduced cytotoxicity to peripheral blood leukocytes, liver, and kidney cells.
radioP↑, Their selective nature makes them suitable for protecting normal cells while inducing cell death in cancer cells during chemotherapy or radiotherapy.
Showing Research Papers: 1 to 5 of 5
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
OXPHOS↑, 1, ROS↑, 2,
Mitochondria & Bioenergetics ⓘ
ATP↓, 1, Insulin↓, 1, MMP↓, 1, OCR↑, 1,
Core Metabolism/Glycolysis ⓘ
AminoA↓, 1, AMPK↑, 1, ATP:AMP↓, 1, glucose↓, 1, GlucoseCon↓, 3, GLUT2↓, 5, Glycolysis↓, 4, HK2↓, 3, lactateProd↓, 3, LDHA↓, 2, PDK1↓, 1, PFK↓, 2, PFK1↓, 2, PKM2↓, 2, PKM2∅, 1, Warburg↓, 2,
Cell Death ⓘ
Apoptosis↑, 2, BAD↑, 1, Casp3↑, 1, Casp8↑, 1, Casp9↑, 1, Cyt‑c↝, 1,
Autophagy & Lysosomes ⓘ
TumAuto↓, 1,
DNA Damage & Repair ⓘ
DNAdam↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
IGF-1↓, 1, mTOR↓, 1, mTORC1↓, 1, PI3K↓, 1, PTEN↑, 1, STAT↓, 1,
Migration ⓘ
PKA↓, 1, TumCP↓, 3,
Angiogenesis & Vasculature ⓘ
Hif1a↓, 1,
Barriers & Transport ⓘ
GLUT1↓, 3,
Immune & Inflammatory Signaling ⓘ
JAK1↓, 1,
Drug Metabolism & Resistance ⓘ
ChemoSen↑, 2, Dose↝, 1, RadioS↑, 1, selectivity↑, 1,
Clinical Biomarkers ⓘ
BG↓, 1,
Functional Outcomes ⓘ
chemoP↓, 1, QoL↑, 1, radioP↑, 1, Risk↓, 1,
Total Targets: 52
Pathway results for Effect on Normal Cells:
Core Metabolism/Glycolysis ⓘ
LDL↓, 1,
Immune & Inflammatory Signaling ⓘ
CRP↓, 1, TNF-α↓, 1,
Drug Metabolism & Resistance ⓘ
Dose↝, 3,
Clinical Biomarkers ⓘ
CRP↓, 1,
Total Targets: 5
Scientific Paper Hit Count for: GLUT2, Glucose Transporter 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1198 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page